Multiple Myeloma
By Laura R. Bobolts, PharmD, BCOP; Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS; Hakan Kaya, MD; Lisa Raff, PharmD, MSPharm, BCPS, BCOP; Yonatan Resnick, PharmD
In this ninth and final installment, Hakan Kaya, MD, Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS, and Lisa Raff, PharmD, MSPharm, BCPS, BCOP, discuss why hospital partnerships are critical to the successful implementation of bispecific agents into regular multiple myeloma treatment practice.
Read Article
By Laura R. Bobolts, PharmD, BCOP; Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS; Hakan Kaya, MD; Lisa Raff, PharmD, MSPharm, BCPS, BCOP; Yonatan Resnick, PharmD
In this eighth installment, Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS, and Yonatan Resnick, PharmD, discuss considerations for preparing a healthcare center’s electronic health record to accommodate bispecific agents in multiple myeloma treatment.
Read ArticleThe researchers noted variations in time to treatment initiation and choice of therapy across the 3 healthcare settings, with factors such as distance from the hospital and income levels playing significant roles in delays of treatment.
Read ArticleOn August 14, 2023, the FDA accelerated the approval of elranatamab-bcmm (Elrexfio; Pfizer), a bispecific B-cell maturation antigen–directed CD3 T-cell engager, for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 previous lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody.
Read ArticleOn August 9, 2023, the FDA accelerated the approval of talquetamab-tgvs (Talvey; Janssen Biotech), a bispecific GPRC5D-directed CD3 T-cell engager, for the treatment of adults with relapsed or refractory multiple myeloma who have previously received at least 4 lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody.
Read ArticleBy Wayne Kuznar
Response to treatment with a regimen of daratumumab (Darzalex) plus lenalidomide (Revlimid; DR) was greater and minimal residual disease (MRD) was achieved more frequently compared with a regimen of lenalidomide plus dexamethasone (Rd) in the first randomized phase 3 clinical trial dedicated to frail, transplant-ineligible patients with newly diagnosed multiple myeloma.
Read ArticleUpdated phase 2 results of the MonumenTAL-1 study showed promising efficacy and a tolerable safety profile with talquetamab, a novel T-cell–redirecting bispecific antibody, in patients with RRMM.
Read ArticleReal-world analysis of patients with MM determines treatment patterns and survival outcomes in patients with t(11;14) compared to patients with high- and standard-risk cytogenetics.
Read ArticleREGN5458, a BCMAxCD38 bispecific antibody, demonstrated early durable responses with a tolerable safety profile and low rates of CRS in patients with relapsed/refractory multiple myeloma.
Read ArticleFinal analysis of ICARIA-MM demonstrated a 6.9-month improvement in survival with Isa-Pd compared to Pd alone in RRMM patients.
Read Article